[go: up one dir, main page]

MX2013012151A - Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos. - Google Patents

Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos.

Info

Publication number
MX2013012151A
MX2013012151A MX2013012151A MX2013012151A MX2013012151A MX 2013012151 A MX2013012151 A MX 2013012151A MX 2013012151 A MX2013012151 A MX 2013012151A MX 2013012151 A MX2013012151 A MX 2013012151A MX 2013012151 A MX2013012151 A MX 2013012151A
Authority
MX
Mexico
Prior art keywords
barrier
forming composition
harmful microorganisms
composition therefor
inhibiting harmful
Prior art date
Application number
MX2013012151A
Other languages
English (en)
Inventor
Brian Sokol
Afif Ghannoum
Original Assignee
ARMS Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARMS Pharmaceutical LLC filed Critical ARMS Pharmaceutical LLC
Publication of MX2013012151A publication Critical patent/MX2013012151A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

En una modalidad, una composición de formación de barrera de carbohidratos incluye una goma, un humectante, y un agente antimicrobiano. La composición además cumple con los siguientes requisitos: aproximadamente 0.01 % = C = aproximadamente 0.4 %; aproximadamente 4.5 % = H = aproximadamente 65 %; y 0.050 % = A; o aproximadamente 0% = C < aproximadamente 0.4 %; aproximadamente 55 % = H = aproximadamente 65 %; y 0.050 % < A. C es la goma de carbohidratos; H es el humectante; y A es el agente antimicrobiano. Todos los porcentajes son en peso de la composición total. En una modalidad, la composición de formación de barrera tiene un valor de Rf en agua de 0 a aproximadamente 0.25. También se provee un método de fabricación y la administración de la composición de formación de barrera para bloquear, neutralizar o matar los microorganismos.
MX2013012151A 2011-04-19 2012-04-17 Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos. MX2013012151A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477147P 2011-04-19 2011-04-19
PCT/US2012/033921 WO2012145307A1 (en) 2011-04-19 2012-04-17 Method of inhibiting harmful microorganisms and barrier-forming composition therefor

Publications (1)

Publication Number Publication Date
MX2013012151A true MX2013012151A (es) 2014-06-20

Family

ID=47021801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012151A MX2013012151A (es) 2011-04-19 2012-04-17 Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos.

Country Status (12)

Country Link
US (4) US8992893B2 (es)
EP (1) EP2699246B1 (es)
JP (2) JP2014518555A (es)
KR (1) KR20140050608A (es)
CN (1) CN103619341A (es)
AU (1) AU2012245665B2 (es)
BR (1) BR112013026965B1 (es)
CA (2) CA3079323A1 (es)
IL (1) IL228956A0 (es)
MX (1) MX2013012151A (es)
RU (1) RU2013151164A (es)
WO (1) WO2012145307A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
MX2013012151A (es) 2011-04-19 2014-06-20 ARMS Pharmaceutical LLC Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos.
WO2013158165A1 (en) * 2012-04-17 2013-10-24 Oasis Consumer Healthcare, Llc. Long-lasting surface anti-microbial and method of application
WO2014107572A1 (en) * 2013-01-04 2014-07-10 ARMS Pharmaceutical LLC Body surface treatment composition and method
EP2941255A4 (en) * 2013-01-04 2016-07-06 ARMS Pharmaceutical LLC Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US10869479B2 (en) * 2014-04-28 2020-12-22 American Sterilizer Company Wipe for killing spores
CN105494418B (zh) * 2014-09-26 2020-08-07 上海玄人信息技术有限公司 一种抑制空气微细颗粒物中有害微生物感染的阻隔剂
CN105497056B (zh) * 2014-09-26 2021-02-19 上海玄人信息技术有限公司 一种抑制空气微细颗粒物侵扰人体的阻隔剂
US10240236B2 (en) * 2015-03-06 2019-03-26 Lam Research Corporation Clean resistant windows for ultraviolet thermal processing
CN106214926A (zh) * 2016-07-29 2016-12-14 腾科宝迪（厦门）生物科技有限公司 一种鼻喷雾剂及其制备方法
CN106668926A (zh) * 2017-03-29 2017-05-17 青岛辰达生物科技有限公司 一种促进伤口愈合凝胶剂的制备方法
US10358717B2 (en) * 2017-04-21 2019-07-23 Lam Research Corporation Method for depositing high deposition rate, thick tetraethyl orthosilicate film with low compressive stress, high film stability and low shrinkage
WO2019069298A2 (en) 2018-01-18 2019-04-11 Christian Arnold CHEMICAL GUM COMPOSITION COMPRISING POLYHEXANIDE
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2023539940A (ja) 2020-09-08 2023-09-20 アルタミラ メディカ， アーゲー 感染を防止するための組成物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683297A (en) 1968-11-22 1972-08-08 Coherent Radiation Lab Optical cavity for a laser
US3993777A (en) 1975-08-12 1976-11-23 Bio-Lab, Inc. Aqueous compositions to aid in the prevention of bovine mastitis
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4657758A (en) * 1984-01-27 1987-04-14 Oral Research Laboratories, Inc. Dental rinse
US4666708A (en) * 1984-01-27 1987-05-19 Oral Research Laboratories, Inc. Dental rinse
US4590057A (en) 1984-09-17 1986-05-20 Rio Linda Chemical Co., Inc. Process for the generation of chlorine dioxide
US4590067A (en) * 1984-10-18 1986-05-20 Peritain, Ltd. Treatment for periodontal disease
US5124359A (en) 1987-12-22 1992-06-23 Cetylite Industries, Inc. Sterilant composition
NO178843C (no) 1988-07-11 1996-06-19 Sspl Sa Safe Sex Prod Licens Fremgangsmåte for fremstilling av et farmasöytisk preparat for å forhindre seksuelt overförbare sykdommer
EP0376363B1 (en) 1988-11-28 1993-01-20 Unilever N.V. Dentifrices containing amino alkyl silicones and sarcosinate surfactants
US5095106A (en) 1989-07-25 1992-03-10 Colgate-Palmolive Olgiosaccharide inhibition of Streptococcus pyogenes adhesion
NO901031L (no) 1990-03-05 1991-09-06 Gunnar Roella Baktericid sammensetning.
US5401723A (en) 1992-12-02 1995-03-28 Colgate-Palmolive Company Glycoconjugate inhibition of Streptococcus pyrogenes adhesion
US20100055152A1 (en) 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
BR9506419A (pt) 1994-10-21 1997-09-09 Japan Clinic Co Ltd Composiçao microbicida e processo de esterilizaçao
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
DE19529862A1 (de) 1995-08-14 1997-02-20 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US6713049B1 (en) 1999-11-12 2004-03-30 The Procter & Gamble Company Oral compositions providing optimal surface conditioning
US5776479A (en) 1996-12-20 1998-07-07 The United States Of America As Represented By The Secretary Of Agriculture Stable, germicidal film-forming teat-dip solutions
US6749869B1 (en) 1997-09-26 2004-06-15 Ecolab Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection
US5938825A (en) 1998-05-21 1999-08-17 Troy Technology Corporation Inc. Stabilized antimicrobial compositions containing halopropynyl compounds
US6207596B1 (en) 1998-11-09 2001-03-27 The Procter & Gamble Company Disposable premoistened wipe containing an antimicrobial protease inhibitor
US6309625B1 (en) 1998-11-12 2001-10-30 Ultradent Products, Inc. One-part dental compositions and methods for bleaching and desensitizing teeth
US7048953B2 (en) * 2000-04-03 2006-05-23 Inhalation, Inc. Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US6666902B1 (en) 2000-05-12 2003-12-23 Nippon Steel Corporation Ladle refining apparatus and ladle refining method using it
US6663902B1 (en) 2000-09-19 2003-12-16 Ecolab Inc. Method and composition for the generation of chlorine dioxide using Iodo-Compounds, and methods of use
US6610276B2 (en) 2001-01-12 2003-08-26 Steven A. Melman Multi-functional dental composition
US7547433B2 (en) * 2001-02-15 2009-06-16 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US6977082B2 (en) 2001-03-29 2005-12-20 The Dial Corporation High efficacy antibacterial compositions having enhanced esthetic and skin care properties
US6682722B2 (en) * 2001-09-19 2004-01-27 The Procter & Gamble Company Oral compositions providing enhanced overall cleaning
AU2003216213B2 (en) * 2002-02-07 2008-10-02 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AU2003282358A1 (en) * 2002-11-21 2004-06-15 J.P.M.E.D. Ltd. Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
US6669929B1 (en) 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US6692726B1 (en) 2003-02-11 2004-02-17 Colgate Palmolive Company Enzyme containing oral composition having enhanced stability
US7071152B2 (en) 2003-05-30 2006-07-04 Steris Inc. Cleaning and decontamination formula for surfaces contaminated with prion-infected material
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US20050025833A1 (en) 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005046738A2 (en) * 2003-11-07 2005-05-26 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
EP2105122B1 (en) 2003-12-16 2012-09-26 Colgate-Palmolive Company Oral and personal care compositions and methods
WO2005067878A1 (en) 2004-01-13 2005-07-28 Vanson Halosource, Inc. Polysaccharide alcohol antiseptic gel
US9241885B2 (en) 2004-01-29 2016-01-26 The Procter & Gamble Company Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials
US20050191270A1 (en) 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
BRPI0514037B8 (pt) 2004-08-02 2021-05-25 Glaxo Group Ltd composição para o cuidado oral
TWI272947B (en) * 2004-09-21 2007-02-11 Far East Bio Tec Co Ltd Pharmaceutical compositions for suppressing influenza virus infection and replication
CN101175474B (zh) * 2005-03-10 2011-09-07 3M创新有限公司 降低微生物污染的方法
AU2006262059B2 (en) 2005-06-22 2008-06-26 Myriad Genetics, Inc. Antiviral compounds
US7467162B2 (en) 2005-06-27 2008-12-16 Microsoft Corporation Pre-configured settings for portable devices
US20070027119A1 (en) 2005-07-29 2007-02-01 Ahmed Fahim U Antibacterial composition and method of use
CA2632183A1 (en) * 2005-08-25 2007-03-01 Philip R. Houle Treatment systems for delivery of sensitizer solutions
JP5001847B2 (ja) 2005-09-27 2012-08-15 旭化成ケミカルズ株式会社 セロオリゴ糖含有組成物
US20070166244A1 (en) * 2006-01-19 2007-07-19 The Procter & Gamble Company Compositions comprising silicone pressure sensitive adhesives for delivering oral care substances
RU2008152101A (ru) 2006-05-31 2010-07-10 Дзе Дайл Корпорейшн (Us) Содержащие спирт противомикробные композиции, обладающие повышенной эффективностью
WO2008026310A1 (fr) * 2006-08-29 2008-03-06 Cellex K.K. Agent protecteur pour une muqueuse orale contenant du tréhalose
AU2007356328A1 (en) 2006-11-14 2009-01-15 Tal Berman Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
EP2100590B2 (en) 2006-11-14 2017-10-04 Sunstar Inc. Oral composition containing crystalline cellulose surface-treated with water-soluble substance
US9271494B2 (en) * 2007-08-30 2016-03-01 Ecolab USA, Inc. Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions
US20090081294A1 (en) 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
BRPI0819819A2 (pt) 2007-11-21 2015-05-26 Procter & Gamble Preparações, método e kits ùteis para o tratamento de tosse
CN101883559B (zh) 2007-12-06 2011-12-28 琳得科株式会社 可食性薄膜
JP2009182220A (ja) 2008-01-31 2009-08-13 Opnext Japan Inc 光伝送モジュール、波長モニタ、および波長ずれ検出方法
US8568697B2 (en) * 2008-03-21 2013-10-29 Colgate-Palmolive Company High fluoride ion recovery compositions
US20130108557A1 (en) * 2009-09-30 2013-05-02 Albert Zorko Abram Cosmetic foam
EP2377577A1 (en) 2010-04-06 2011-10-19 Panaxia Ltd A benzyl alcohol mixture for treating premature ejaculation
US10449139B2 (en) * 2010-12-23 2019-10-22 Colgate-Palmolive Company Aqueous oral care compositions
MX2013012151A (es) 2011-04-19 2014-06-20 ARMS Pharmaceutical LLC Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos.
US20130123308A1 (en) 2011-04-19 2013-05-16 Oasis Consumer Healthcare, Llc Long-lasting surface anti-microbial and method of application
US20140051732A1 (en) 2011-04-19 2014-02-20 Arm Pharmaceutical Llc Low-tack surface anti-microbial coating composition and method of application
US20130123309A1 (en) 2011-04-19 2013-05-16 Oasis Consumer Healthcare Llc Method for reducing microbial load for individuals with elevated risk conditions
US20130039959A1 (en) 2011-04-19 2013-02-14 Brian Vincent Sokol Method of inhibiting hiv and barrier-forming composition therefor
WO2013158165A1 (en) 2012-04-17 2013-10-24 Oasis Consumer Healthcare, Llc. Long-lasting surface anti-microbial and method of application
WO2014074331A1 (en) 2012-11-12 2014-05-15 ARMS Pharmaceutical LLC Low-tack surface anti-microbial coating composition and method of application
JP2016504383A (ja) 2013-01-04 2016-02-12 アームズ ファーマシューティカル エルエルシーＡｒｍｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌｌｃ． 体表面処理組成物及び処理方法
WO2014107572A1 (en) 2013-01-04 2014-07-10 ARMS Pharmaceutical LLC Body surface treatment composition and method
EP2941255A4 (en) 2013-01-04 2016-07-06 ARMS Pharmaceutical LLC Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US20150306042A1 (en) 2013-01-04 2015-10-29 ARMS Pharmaceutical LLC Body surface treatment composition and method

Also Published As

Publication number Publication date
BR112013026965A2 (pt) 2017-01-10
AU2012245665B2 (en) 2017-06-15
EP2699246B1 (en) 2023-06-14
US20120270909A1 (en) 2012-10-25
IL228956A0 (en) 2013-12-31
CA3079323A1 (en) 2012-10-26
WO2012145307A1 (en) 2012-10-26
RU2013151164A (ru) 2015-05-27
AU2012245665A1 (en) 2013-10-24
EP2699246A1 (en) 2014-02-26
CA2832854A1 (en) 2012-10-26
US20140005236A1 (en) 2014-01-02
EP2699246A4 (en) 2014-10-08
CN103619341A (zh) 2014-03-05
US8992893B2 (en) 2015-03-31
US20190358149A1 (en) 2019-11-28
JP6831227B2 (ja) 2021-02-17
US10398645B2 (en) 2019-09-03
CA2832854C (en) 2020-04-28
KR20140050608A (ko) 2014-04-29
BR112013026965B1 (pt) 2019-04-02
JP2014518555A (ja) 2014-07-31
EP2699246C0 (en) 2023-06-14
US8535646B2 (en) 2013-09-17
JP2017081951A (ja) 2017-05-18
US20130028848A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
MX2013012151A (es) Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos.
WO2014099226A3 (en) Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
MX2010010135A (es) Derivados de hidroximoil-tetrazol fungicidas.
MX2014000468A (es) Composiciones plaguicidas y procesos relacionados.
MX352985B (es) Formulaciones desinfectantes topicas y uso de las mismas.
MX2012001800A (es) Composicion para el cuidado oral que comprende agente sesquiterpenoide y antimicrobiano.
MX2010007677A (es) Derivados de hidroximoil-tetrazol como fungicidas.
RS54548B1 (en) COMPOSITIONS CONTAINING ORGANIC ACID MONOGLICERIDES WITH C1 TO C7 AND GLYCEROL, THEIR PREPARATION AND USE AS ANTIBACTERIAL AND ANTIGLIVIC AGENAS
EP3292764A3 (en) Composition comprising a biological control agent and a fungicide selected from inhibitors of the respiratory chain at complex iii
MX2009003378A (es) Concentrados en suspension para la mejora de la absorcion por la raiz de principios activos agroquimicos.
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
MX2011011229A (es) Metodo para reducir la presion intraocular en los seres humanos.
PH12013500721A1 (en) Oral care product and methods of use and manufacture thereof
AR075274A1 (es) Agente de tratamiento de semillas y metodo para proteger una planta
MX336392B (es) Derivados de hidroximoil-heterociclos fungicidas.
MY163476A (en) Oral care compositions
UA104994C2 (uk) Придатна для розпилення композиція, що містить екстракт із листя червоного винограду
WO2011001111A3 (fr) Utilisation d&#39;un composé d&#39;acide jasmonique pour traiter la peau grasse
UA109460C2 (uk) N-гетарилметилпіразолілкарбоксаміди
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
SG194410A1 (en) Skin treatments containing carboxylic acid-substituted idebenone derivatives and methods of preparation and use thereof
MY159020A (en) Composition and method for controlling plant diseases
PH12012502253A1 (en) Oral care compositions and methods
WO2011015524A3 (en) Fungicide heterocycles derivatives
WO2014006601A3 (en) Nanoparticle compositions of antibacterial compounds and other uses thereof